Regeneron is facing two FDA decisions for its T-cell engagers.
ApexOnco Front Page
Recent articles
The Avanzar study could read out shortly.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
The group is persevering with Granite, but funds might be hard to come by.
First-in-human trial initiations reveal four KRAS assets.
For $850m up front Roche gets to challenge Pfizer.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.